- Home
- CELC vs NVG Comparison
CELC vs NVG Comparison
Compare CELC & NVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- NVG
- Stock Information
- Founded
- CELC 2011
- NVG 1999
- Country
- CELC United States
- NVG United States
- Employees
- CELC N/A
- NVG N/A
- Industry
- CELC Medical Specialities
- NVG Investment Managers
- Sector
- CELC Health Care
- NVG Finance
- Exchange
- CELC Nasdaq
- NVG Nasdaq
- Market Cap
- CELC 2.3B
- NVG 2.6B
- IPO Year
- CELC 2017
- NVG N/A
- Fundamental
- Price
- CELC $50.51
- NVG $12.28
- Analyst Decision
- CELC Strong Buy
- NVG
- Analyst Count
- CELC 6
- NVG 0
- Target Price
- CELC $63.00
- NVG N/A
- AVG Volume (30 Days)
- CELC 1.0M
- NVG 568.8K
- Earning Date
- CELC 11-13-2025
- NVG 01-01-0001
- Dividend Yield
- CELC N/A
- NVG 4.65%
- EPS Growth
- CELC N/A
- NVG N/A
- EPS
- CELC N/A
- NVG N/A
- Revenue
- CELC N/A
- NVG N/A
- Revenue This Year
- CELC N/A
- NVG N/A
- Revenue Next Year
- CELC N/A
- NVG N/A
- P/E Ratio
- CELC N/A
- NVG N/A
- Revenue Growth
- CELC N/A
- NVG N/A
- 52 Week Low
- CELC $7.58
- NVG $9.68
- 52 Week High
- CELC $63.06
- NVG $12.21
- Technical
- Relative Strength Index (RSI)
- CELC 49.45
- NVG 57.06
- Support Level
- CELC $44.42
- NVG $12.24
- Resistance Level
- CELC $52.76
- NVG $12.44
- Average True Range (ATR)
- CELC 3.10
- NVG 0.10
- MACD
- CELC -1.11
- NVG -0.01
- Stochastic Oscillator
- CELC 51.39
- NVG 50.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About NVG Nuveen AMT-Free Municipal Credit Income Fund
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.